
Photograph courtesy of Georgia Tech
When a patient is in heart failure, they are often hospitalized over and over again, with high mortality rates. But Georgia Tech professor Omer Inan is hoping to change that with an innovation that recently received FDA clearance. Called CardioTag, the device, which uses wearable sensors to measure physiological signals from the heart, is paired with start-up company CardioSense’s AI to change the way heart failure patients are monitored, which could reduce hospitalizations.
Inan says part of that is because the right tools to monitor them at home and in the hospital haven’t been available. Now, with CardioTag, clinicians can get comprehensive information to see patterns and hopefully intervene before it becomes an emergency. Inan has been working on it while at Georgia Tech, in collaboration with the University of California San Francisco.

Photograph courtesy of Georgia Tech
CardioTag has three signals it monitors: electrocardiograms, or the heart’s electrical activity; photoplethysmograms, or the pulse signal; and seismocardiograms, or the heart’s mechanical vibrations. “Seismocardiograms are the tiny earthquakes of your chest in response to your heartbeat,” he says. Inan has been studying seismocardiograms since he was in graduate school at Stanford decades ago, and it was first measured in astronauts in the 1960s. “That signal gives us the most important information, which is the mechanical activity of the heart: how it’s being filled and pumping.”
Today, clinicians often rely on implantable sensors that measure cardiac filling pressures. However, it’s invasive, has risks, and pricey, costing close to $30,000.

Photograph courtesy of Georgia Tech
Now, CardioTag’s wearable device and companion app can monitor all three markers to give the patient, caregiver, and hospital staff more comprehensive data. “It may allow them to stay at a better level of filling pressure at home, and not have those pressures go up and cause hospitalization,” says Inan. “It’s kind of like an Apple Watch for your heart.”
CardioTag, which will be available by prescription, plans to start early stage pilots and commercialization pilots later this year, with a full ramp-up in 2027.



